Kolltan Pharmaceuticals Inc. Appoints Ronald A. Peck, M.D., Chief Medical Officer And SVP, Clinical Development

NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, Inc. ("Kolltan" or the "Company"), a privately held clinical-stage company focused on the discovery and development of novel, best-in-class antibody-based drugs targeting receptor tyrosine kinases for the treatment of cancer and other diseases, today announced the appointment of Ronald A. Peck, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development.

Suggested Articles

The top dose of Regeneron's COVID-19 antibody lowered virus levels and relieved symptoms more quickly than placebo in non-hospitalized patients.

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.